Randomised Prospective Trial Comparing Contact Force and Non-contact Force Guided Catheter Ablation for Cavotricuspid Isthmus Dependent Atrial Flutter
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02825498 |
Recruitment Status :
Enrolling by invitation
First Posted : July 7, 2016
Last Update Posted : April 25, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Atrial Flutter Radiofrequency Catheter Ablation | Device: Contact force guided RFA | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Randomised Prospective Trial Comparing Contact Force and Non-contact Force Guided Catheter Ablation for Cavotricuspid Isthmus Dependent Atrial Flutter |
Actual Study Start Date : | May 18, 2016 |
Estimated Primary Completion Date : | July 2020 |
Estimated Study Completion Date : | July 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Operator guided by contact force
Operator has full access to contact force parameters including force time integral (FTI).
|
Device: Contact force guided RFA
Contact force guided RFA during Atrial Flutter ablation procedure. |
No Intervention: Operator blinded to contact force
Operator is blinded to contact force with ablation guided by standard markers of effective ablation.
|
- Efficacy of RFA [ Time Frame: Determined during RFA procedure ]Total RFA time required to achieve bidirectional block
- Recurrence of atrial flutter [ Time Frame: Assessed at 12 weeks and 12 months post CTI RFA procedure ]Documented recurrence of atrial flutter
- Average total CF achieved [ Time Frame: Determined during RFA procedure ]Average total CF per ablation per segment (third) of the CTI.
- Average axial CF achieved [ Time Frame: Determined during RFA procedure ]Average axial CF per ablation per segment (third) of the CTI.
- Average FTI achieved [ Time Frame: Determined during RFA procedure ]Average FTI per ablation per segment (third) of the CTI.
- Average lateral CF achieved [ Time Frame: Determined during RFA procedure ]Average lateral CF per ablation per segment (third) of the CTI.
- Average lesion size index (LSI) achieved [ Time Frame: Determined during RFA procedure ]Average lesion size index (LSI) per ablation per segment (third) of the CTI.
- Procedural complication rate [ Time Frame: Determined during RFA procedure and at 12 weeks post RFA procedure ]Incidence of procedural complications: stroke, cardiac perforation, steam pops, access site bleeding.
- Average total CF of segment of acute and delayed reconnection [ Time Frame: Determined during index and repeat RFA procedure ]Average total CF per ablation in segment (third) of acute or delayed reconnection.
- Average lateral CF of segment of acute and delayed reconnection [ Time Frame: Determined during index and repeat RFA procedure ]Average lateral CF per ablation in segment (third) of acute or delayed reconnection.
- Average axial CF of segment of acute and delayed reconnection [ Time Frame: Determined during index and repeat RFA procedure ]Average axial CF per ablation in segment (third) of acute or delayed reconnection.
- Average FTI of segment of acute and delayed reconnection [ Time Frame: Determined during index and repeat RFA procedure ]Average FTI per ablation in segment (third) of acute or delayed reconnection.
- Average lesion size index (LSI) of segment of acute and delayed reconnection [ Time Frame: Determined during index and repeat RFA procedure ]Average lesion size index (LSI) per ablation in segment (third) of acute or delayed reconnection.
- Procedural efficacy of RFA [ Time Frame: Determined during RFA procedure ]Total procedural time required to achieve bidirectional block

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Adult patients (over the age of 18) with 12 lead ECG documented paroxysmal or persistent CTI dependent atrial flutter planned to undergo CTI ablation.
- Able and willing to give informed consent.
Exclusion Criteria:
- Previous CTI ablation
- Previous non-CTI dependent atrial flutter (ie.patients with previous history of pulmonary vein isolation or left atrial ablation, congenital heart disease, surgical ablation)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02825498
Canada, British Columbia | |
Victoria Cardiac Arrhythmia Trials | |
Victoria, British Columbia, Canada |
Principal Investigator: | Paul Novak, MD | Victoria Cardiac Arrhythmia Trials |
Responsible Party: | Victoria Cardiac Arrhythmia Trials |
ClinicalTrials.gov Identifier: | NCT02825498 History of Changes |
Other Study ID Numbers: |
C2016-012 |
First Posted: | July 7, 2016 Key Record Dates |
Last Update Posted: | April 25, 2019 |
Last Verified: | April 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | De-identified IPD may be shared with other researchers upon study completion. Data may be obtained by contacting Victoria Cardiac Arrhythmia Trials Inc. at 250-595-0400. |
Atrial Flutter Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |